Early analysis of Pfizer shows 90% efficacy
Kathmandu. The manufacturer of the vaccine against the novel coronavirus, Pfizer has claimed that they have achieved an effectiveness of more than 90%, in early analysis.
CNN reported that the so-called interim analysis looked at the first 94 confirmed cases of COVID-19 among more than 43,000 volunteers who got either two doses of the vaccine or a placebo and found fewer than 10% of infections in participants who had been given the vaccine while more than 90% of the cases were in people who had been given a placebo.
Pfizer plans to seek emergency authorization of the two-dose vaccine later this month from the Food and Drug Administration after it has collected the recommended two months of safety data. As per The New York Times, company executives are positive that by the end of the year they will have manufactured enough doses to immunize 15 to 20 million people.
Several scientists have warned to be wary of the long-term safety and efficacy since it is a novice one. However, the positive result is still monumental in the desperate times with the pandemic looming above.
Facebook Comment
Related News
latest Video
Trending News
- This Week
- This Month
